Sei Investments Co. Grows Position in Amylyx Pharmaceuticals, Inc. $AMLX

Sei Investments Co. grew its holdings in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 61.3% in the first quarter, HoldingsChannel.com reports. The fund owned 85,279 shares of the company’s stock after purchasing an additional 32,423 shares during the period. Sei Investments Co.’s holdings in Amylyx Pharmaceuticals were worth $1,185,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Adage Capital Partners GP L.L.C. increased its position in shares of Amylyx Pharmaceuticals by 54.5% in the second quarter. Adage Capital Partners GP L.L.C. now owns 8,800,000 shares of the company’s stock worth $56,408,000 after purchasing an additional 3,102,395 shares during the last quarter. Millennium Management LLC lifted its position in Amylyx Pharmaceuticals by 418.6% during the first quarter. Millennium Management LLC now owns 3,081,853 shares of the company’s stock valued at $10,910,000 after purchasing an additional 2,487,617 shares during the last quarter. Janus Henderson Group PLC lifted its position in Amylyx Pharmaceuticals by 76.1% during the fourth quarter. Janus Henderson Group PLC now owns 4,465,872 shares of the company’s stock valued at $53,992,000 after purchasing an additional 1,929,639 shares during the last quarter. Paradigm Biocapital Advisors LP purchased a new position in Amylyx Pharmaceuticals in the 3rd quarter worth approximately $25,821,000. Finally, Commodore Capital LP grew its stake in Amylyx Pharmaceuticals by 38.6% in the 4th quarter. Commodore Capital LP now owns 5,650,000 shares of the company’s stock worth $68,252,000 after buying an additional 1,574,522 shares in the last quarter. Hedge funds and other institutional investors own 95.84% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Wall Street Zen lowered shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Guggenheim lifted their price objective on shares of Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, June 25th. Citigroup upped their target price on shares of Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Mizuho increased their target price on Amylyx Pharmaceuticals from $21.00 to $24.00 and gave the company an “outperform” rating in a research note on Monday, July 20th. Finally, HC Wainwright restated a “buy” rating and set a $34.00 price target on shares of Amylyx Pharmaceuticals in a research report on Monday, June 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $25.38.

Insider Transactions at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 15,000 shares of the company’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $18.32, for a total transaction of $274,800.00. Following the completion of the sale, the insider directly owned 194,090 shares in the company, valued at $3,555,728.80. This represents a 7.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 10.90% of the stock is currently owned by insiders.

Key Headlines Impacting Amylyx Pharmaceuticals

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: Amylyx was identified by Zacks as one of four biotech companies with major second-half 2026 catalysts. The potential catalysts include regulatory decisions and late-stage clinical-trial readouts, which could provide important updates on the company’s pipeline and support investor optimism. 4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $34 price target for Amylyx. The target implies further upside from recent trading levels and may have helped reinforce the bullish view among investors. Amylyx Pharmaceuticals Analyst Coverage
• Neutral Sentiment: Reported short interest was listed at zero shares, unchanged from the prior reporting period, with a zero-day days-to-cover ratio. Because the figures appear anomalous, they provide little meaningful information about short-selling pressure or potential short-covering demand.
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across the 2026–2028 period, including estimates of losses of $1.49 per share for fiscal 2026, $1.40 for fiscal 2027, and $1.08 for fiscal 2028. Quarterly loss estimates were also lowered to $0.35 per share for the third quarter of 2026 and $0.37 for the fourth quarter, signaling expectations for continued cash burn and weaker profitability than previously projected. HC Wainwright Amylyx Estimates

Amylyx Pharmaceuticals Stock Performance

Shares of AMLX opened at $23.63 on Wednesday. Amylyx Pharmaceuticals, Inc. has a fifty-two week low of $7.63 and a fifty-two week high of $24.60. The firm has a market cap of $2.63 billion, a price-to-earnings ratio of -16.52 and a beta of -0.21. The firm has a 50 day moving average price of $17.74 and a 200-day moving average price of $15.86.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its earnings results on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.03). As a group, equities research analysts predict that Amylyx Pharmaceuticals, Inc. will post -1.42 earnings per share for the current year.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.